| ORIGINAL ARTICLE |
|
| Year : 2018 | Volume
: 7
| Issue : 1 | Page : 33-38 |
|
|
Thyroid dysfunction in chronic myeloid leukemia patients on nilotinib
Khaleed J Khaleel1, Ahmed H Matloob2, Abdalsalam Hatim3
1 Department of Genetics, The Iraqi Centre for Cancer and Medical Genetic Research, Al-Mustansiriyah University, Karbala, Iraq
2 Department of Pharmacology, University of Karbala, College of Medicine, Karbala, Iraq
3 National Center of Hematology, Al-Mustansiriyah University, Baghdad, Iraq
Correspondence Address:
Dr. Khaleed J Khaleel
Department of Genetics, The Iraqi Centre for Cancer and Medical Genetic Research, Al-Mustansiriyah University, Baghdad
Iraq
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijh.ijh_39_17
|
|
|
Background: The use of tyrosine kinase inhibitors has dramatically improved the prognosis of chronic myeloid leukemia (CML). Nilotinib has been reported to be associated with hypothyroidism and hyperthyroidism.
Objectives: The current study aims to evaluate the prevalence of thyroid dysfunction in a sample of Iraqi patients with CML (chronic phase) treated with nilotinib and its possible association with grade of other hematological parameters.
Patients and Methods: Thirty-one patients with CML and the same number of healthy controls were enrolled in this cross-sectional study. All the patients were on nilotinib hydrochloride for at least 6 months.
Results: Approximately 10% of the patients were having hypothyroidism and 3% were hyperthyroid while the rest (87%) were normal regarding thyroid function. There was a significant difference between the study and control group in thyroid stimulating hormone levels (P < 0.05) with the level being higher in the study group.
Conclusion: Thyroid dysfunction, particularly hypothyroidism is a clinically important adverse effect of nilotinib. Monitoring of thyroid function is required for patients taking this drug.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
